MX2023008716A - Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. - Google Patents
Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo.Info
- Publication number
- MX2023008716A MX2023008716A MX2023008716A MX2023008716A MX2023008716A MX 2023008716 A MX2023008716 A MX 2023008716A MX 2023008716 A MX2023008716 A MX 2023008716A MX 2023008716 A MX2023008716 A MX 2023008716A MX 2023008716 A MX2023008716 A MX 2023008716A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- application
- compound
- camptothecin compound
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title abstract 2
- -1 Camptothecin compound Chemical class 0.000 title abstract 2
- 229940127093 camptothecin Drugs 0.000 title abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110159956 | 2021-02-05 | ||
| CN202110533304 | 2021-05-17 | ||
| CN202110718245 | 2021-06-28 | ||
| CN202110936768 | 2021-08-16 | ||
| CN202111355330 | 2021-11-16 | ||
| PCT/CN2022/074328 WO2022166762A1 (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008716A true MX2023008716A (es) | 2023-08-02 |
Family
ID=82741966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008716A MX2023008716A (es) | 2021-02-05 | 2022-01-27 | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240158410A1 (enExample) |
| EP (3) | EP4289851A4 (enExample) |
| JP (3) | JP7821188B2 (enExample) |
| KR (3) | KR20230142710A (enExample) |
| CN (3) | CN116829561A (enExample) |
| AU (1) | AU2022216696A1 (enExample) |
| CA (1) | CA3209426A1 (enExample) |
| MX (1) | MX2023008716A (enExample) |
| WO (1) | WO2022166762A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121944137A (zh) | 2020-09-30 | 2026-05-01 | 映恩生物制药（苏州）有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
| AU2021359457A1 (en) * | 2020-10-12 | 2023-05-11 | Systimmune, Inc. | Camptothecin derivative and its ligand-drug conjugate |
| MX2023008716A (es) * | 2021-02-05 | 2023-08-02 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US12545716B2 (en) | 2021-07-19 | 2026-02-10 | Immunome, Inc. | Immunoconjugates and methods |
| EP4389752A4 (en) * | 2021-08-19 | 2025-08-20 | Hainan Simcere Zaiming Pharmaceutical Co Ltd | CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND THEIR USE |
| US20250059143A1 (en) * | 2021-10-26 | 2025-02-20 | Shanghai Best-Link Bioscience, Llc | Camptothecin derivative intermediate, and preparation method therefor and use thereof |
| CA3237844A1 (en) | 2021-11-15 | 2023-05-19 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN118696048A (zh) * | 2022-05-09 | 2024-09-24 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| EP4524140A1 (en) | 2022-05-13 | 2025-03-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor and use thereof |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| US20260021193A1 (en) * | 2022-07-26 | 2026-01-22 | Immunome, Inc. | Immunoconjugates and methods |
| KR20250053961A (ko) * | 2022-09-02 | 2025-04-22 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도 |
| CN121064209A (zh) * | 2022-09-09 | 2025-12-05 | 杭州爱科瑞思生物医药有限公司 | 喜树碱-7-乙基胺衍生物及其制备方法和应用 |
| KR20250069963A (ko) * | 2022-09-30 | 2025-05-20 | 베이진 스위찰랜드 게엠베하 | 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도 |
| AU2023359114A1 (en) | 2022-10-09 | 2025-04-24 | LaNova Medicines Limited | Compounds, compositions and methods |
| TW202432099A (zh) * | 2022-10-25 | 2024-08-16 | 美商默沙東有限責任公司 | 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途 |
| US20260001891A1 (en) * | 2022-11-22 | 2026-01-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| CN118105508A (zh) * | 2022-11-29 | 2024-05-31 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| CN116712563A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116870187A (zh) * | 2022-12-29 | 2023-10-13 | 杭州爱科瑞思生物医药有限公司 | N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712562A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 |
| JP2026504160A (ja) * | 2023-01-25 | 2026-02-03 | イムノーム，インク． | エキサテカン免疫コンジュゲート |
| JP2026510566A (ja) * | 2023-02-23 | 2026-04-08 | フロントライン バイオファーマ （ハンチョウ） カンパニー リミテッド | カンプトテシン誘導体及びその複合体、並びにその調製方法および医療用途 |
| EP4674851A1 (en) * | 2023-03-01 | 2026-01-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for indolizino[1,2-b]quinoline-10,13-dione derivative |
| JP2026513781A (ja) * | 2023-04-07 | 2026-05-01 | 長春金賽薬業有限責任公司 | カンプトテシン誘導体、医薬組成物及びその製造方法と応用 |
| CN116478051B (zh) * | 2023-04-13 | 2024-06-21 | 戊言医药科技（上海）有限公司 | 一种贝洛替康盐酸盐及其关键中间体的制备方法 |
| CN118878548A (zh) * | 2023-04-30 | 2024-11-01 | 泰诚思(上海)生物医药有限公司 | 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用 |
| CN120826405A (zh) * | 2023-05-04 | 2025-10-21 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| CN117417346B (zh) * | 2023-09-11 | 2025-07-25 | 常州合全药业有限公司 | 喜树碱类衍生物的制备方法 |
| KR20250059577A (ko) | 2023-10-24 | 2025-05-07 | 삼성디스플레이 주식회사 | 표시 장치 |
| CN120000805A (zh) * | 2023-11-15 | 2025-05-16 | 四川科伦博泰生物医药股份有限公司 | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 |
| CN120058720A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用 |
| CN120058721A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-氟烷基取代的喜树碱衍生物的制备及其应用 |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| WO2025242090A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 喜树碱衍生物及其中间体的制备方法 |
| WO2026046398A1 (en) * | 2024-08-30 | 2026-03-05 | Hansoh Bio Llc | Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| MX9710228A (es) * | 1995-06-21 | 1998-03-31 | Sod Conseils Rech Applic | Nuevos analogos de camptotecina, procedimientos de preparacion, su aplicacion como medicinas y las composiciones farmaceuticas que los comprenden. |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| CN100408582C (zh) * | 2004-02-12 | 2008-08-06 | 中国人民解放军第二军医大学 | 高喜树碱类化合物及其制备方法和用途 |
| US11091498B2 (en) * | 2016-04-04 | 2021-08-17 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
| WO2019011170A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
| CN119241554A (zh) * | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| BR112021004656A2 (pt) * | 2018-09-26 | 2021-06-01 | Jiangsu Hengrui Medicine Co., Ltd. | conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo |
| MY209065A (en) * | 2018-09-30 | 2025-06-18 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CR20210541A (es) * | 2019-03-29 | 2021-12-20 | Medimmune Ltd | Compuestos y conjugados de estos |
| HUE065484T2 (hu) * | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| CN110357897A (zh) * | 2019-07-26 | 2019-10-22 | 上海健康医学院 | 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用 |
| AU2020347715A1 (en) * | 2019-09-18 | 2022-04-07 | Systimmune, Inc. | Camptothecin derivative and conjugate thereof |
| TWI891714B (zh) * | 2020-01-22 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗trop-2抗體-依喜替康類似物偶聯物及其醫藥用途 |
| WO2021249228A1 (zh) * | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物 |
| EP4227309A4 (en) * | 2020-10-12 | 2024-11-27 | Sichuan Baili Pharmaceutical Co. Ltd. | DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF |
| MX2023008716A (es) * | 2021-02-05 | 2023-08-02 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. |
| WO2022253035A1 (zh) * | 2021-06-02 | 2022-12-08 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| US20240252665A1 (en) * | 2021-06-02 | 2024-08-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN117567487A (zh) * | 2023-11-27 | 2024-02-20 | 金宏气体股份有限公司 | 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用 |
-
2022
- 2022-01-27 MX MX2023008716A patent/MX2023008716A/es unknown
- 2022-01-27 KR KR1020237025527A patent/KR20230142710A/ko active Pending
- 2022-01-27 AU AU2022216696A patent/AU2022216696A1/en active Pending
- 2022-01-27 CN CN202280008418.XA patent/CN116829561A/zh active Pending
- 2022-01-27 EP EP22749041.4A patent/EP4289851A4/en active Pending
- 2022-01-27 WO PCT/CN2022/074328 patent/WO2022166762A1/zh not_active Ceased
- 2022-01-27 CN CN202510232225.8A patent/CN120058723A/zh active Pending
- 2022-01-27 JP JP2023544762A patent/JP7821188B2/ja active Active
- 2022-01-27 CN CN202311518671.2A patent/CN117567478B/zh active Active
- 2022-01-27 CA CA3209426A patent/CA3209426A1/en active Pending
- 2022-01-27 EP EP25191605.2A patent/EP4613335A3/en active Pending
- 2022-01-27 US US18/262,821 patent/US20240158410A1/en active Pending
- 2022-01-27 EP EP25191607.8A patent/EP4628165A3/en active Pending
- 2022-01-27 KR KR1020257024904A patent/KR20250119655A/ko active Pending
- 2022-01-27 KR KR1020257024905A patent/KR20250120438A/ko active Pending
-
2025
- 2025-07-24 JP JP2025123921A patent/JP2025160317A/ja active Pending
- 2025-07-24 JP JP2025123923A patent/JP2025160318A/ja active Pending
- 2025-07-24 US US19/279,242 patent/US20250346606A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120058723A (zh) | 2025-05-30 |
| EP4613335A2 (en) | 2025-09-10 |
| US20240158410A1 (en) | 2024-05-16 |
| EP4628165A2 (en) | 2025-10-08 |
| US20250346606A1 (en) | 2025-11-13 |
| JP2025160318A (ja) | 2025-10-22 |
| JP2024506819A (ja) | 2024-02-15 |
| AU2022216696A1 (en) | 2023-08-17 |
| EP4613335A3 (en) | 2025-12-10 |
| CA3209426A1 (en) | 2022-08-11 |
| KR20250120438A (ko) | 2025-08-08 |
| KR20230142710A (ko) | 2023-10-11 |
| CN117567478B (zh) | 2025-03-21 |
| CN117567478A (zh) | 2024-02-20 |
| CN116829561A (zh) | 2023-09-29 |
| JP2025160317A (ja) | 2025-10-22 |
| KR20250119655A (ko) | 2025-08-07 |
| EP4628165A3 (en) | 2026-03-11 |
| WO2022166762A1 (zh) | 2022-08-11 |
| EP4289851A1 (en) | 2023-12-13 |
| EP4289851A4 (en) | 2025-10-15 |
| JP7821188B2 (ja) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4613335A3 (en) | Camptothecin compound, preparation method therefor, and application thereof | |
| ZA202308118B (en) | Cdk inhibitor | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MY210283A (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| NZ543661A (en) | Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| MX2014002555A (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| MX2025009943A (es) | Derivado de camptotecina, su conjugado, su metodo de preparacion y su uso medico | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| MX2022004739A (es) | Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo. | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| AU2013330679A8 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| PH12022550254A1 (en) | MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| MX2025012133A (es) | Derivados de tiadiazolona, composiciones y usos de estos |